Navigation Links
MiMedx Announces Record First Quarter 2013 Results
Date:5/1/2013

anization to fuel future revenue growth against near term EBITDA growth.

Once again, our revenue growth was primarily driven by our EpiFix® wound care allografts with increased utilization in numerous Veterans Administration (VA) Hospitals, as well as very positive growth in the non-government sectors driven by the five Medicare Administrative Contractor (MAC) approvals during the quarter. Our direct sales force strategy is increasing the pace of our revenue growth and we are continuing to add additional sales executives in both the government sector and the commercial sector. At the end of the quarter, we had 28 sales executives dedicated to our direct sales force focused on the government sector, 18 sales executives dedicated to our direct commercial wound care sales force and 5 sales executives focused on the surgical and orthopedic market managing a strong network of independent sales distributors."

During the quarter, the Company continued to expand its resources focused on clinical research. "Within the next few months, we expect to publish results from three of our clinical studies. In addition, our clinical research team has been working on studies related to the characterization and mechanism of action of our tissue grafts, and we expect the results of some of these studies will soon be published as well," added Petit.

Bill Taylor, President and COO, commented, "We received the Medicare Q code on January 1st of this year. As we have stated previously, the follow-up work to gain reimbursement approval from the Medicare intermediaries is critical. We have aggressively pursued this aspect of our reimbursement strategy and five of the nine MACs have begun to reimburse for our EpiFix® wound care tissue grafts. We believe that our studies published to date that support the efficacy and cost-effectiveness of our allografts and the results we expect to be able to report in upcoming publications will be extremely influentia
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
2. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
3. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
4. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
5. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
6. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
7. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
8. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
9. MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference
10. MiMedx Group to Present at the BIOX; Noble Financial Capital Markets Life Sciences Exposition
11. MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014 The chemistry, taste, and health effects of ... article published by the nonprofit American Botanical Council (ABC). Recent ... and its effects on the phytochemical compounds in tea ( ... by Dr. Ahmed in the Yunnan ... implications for the future of medicinal botanicals. Dr. Ahmed,s ...
(Date:9/15/2014)... 15. September 2014 Die zweite jährliche ... vom 12. bis 18. Oktober stattfinden. Die IPAW ... Therapeutics Association (PPTA) und ihrer Mitgliedsunternehmen ... Das globale Bewusstsein für die Gewinnung von Quellplasma ... beim Retten und Verbessern von Leben zu würdigen ...
(Date:9/15/2014)... , 15 de septiembre de 2014 La segunda ... a cabo del 12 al 18 de octubre. Como iniciativa ... y de sus compañías miembro s, la IPAW se ... mundial en torno a la colección de fuentes de plasma ... plasma al salvar y mejorar las vidas , Aumento ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 Hydro ... ) announced today that it will be partnering ... CA ( http://www.proteaf.com ) for implementing its Shock ... value continuous processing. Continuous flow chemistry through ... chemical, pharmaceutical and petrochemical markets for decades. ...
Breaking Biology Technology:Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3La International Plasma Awareness Week será una celebración para los donantes 2La International Plasma Awareness Week será una celebración para los donantes 3Hydro Dynamics Partners with the Continuous Flow Chemistry Experts of Proteaf Technologies 2
... Ohio -- In the quest for smaller, faster computer ... the exotic physics of the small. The problem: ... been equally exotic. That is, until now. ... to make quantum devices using technology common to the ...
... 15 Today, Formatech, Inc. announced that ... HIV/AIDS vaccine will be the first clinical candidate that is ... run is scheduled to be completed in January 2010. ... aseptically fill and finish one lot of the vaccine for ...
... 15 SIRO Clinpharm, a global Contract Research Organization (CRO) ... announced expansion of its Clinical Trials Supplies facility in Mumbai, ... pharmaceutical and biotech companies for storage and distribution of clinical ... , "We opened our clinical trials supplies warehouse ...
Cached Biology Technology:Quantum computer chips now 1 step closer to reality 2Quantum computer chips now 1 step closer to reality 3Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 2Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 3Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 4SIRO Clinpharm Strengthens its Clinical Trials Supplies Service Offering in India 2
(Date:9/15/2014)... Globally, cardiovascular disease (CVD) claims 17 million lives each ... additional 9.4 million. 1 New research presented by ... in Montpellier, France on September 15, 2014, suggests that ... , At the Milk and Dairy Products ... and risk for hypertension and CVD was examined by ...
(Date:9/15/2014)... the need for vitamin E and how much is ... levels of this essential micronutrient are especially critical for ... or may become pregnant. , A lifelong proper intake ... often complicated by the fact that this nutrient is ... alone. It has been estimated that only a tiny ...
(Date:9/12/2014)... DUBLIN, Ireland , September 12, 2014 ... and Markets ( http://www.researchandmarkets.com/research/trs4c7/global ) has announced ... Lock Industry Report 2014" report to ... Fingerprint Lock Industry Report 2014 is a ... state of the global fingerprint lock industry. ...
Breaking Biology News(10 mins):Dairy consumption linked to lower blood pressure and cardiovascular disease risk 2Vitamin E intake critical during 'the first 1,000 days' 2Vitamin E intake critical during 'the first 1,000 days' 3Global Fingerprint Lock Industry Report 2014 2
... Spanish . Losses of managed honey bee ... 2009 to April 2010, according to a survey conducted by ... Service (ARS). Beekeepers identified starvation, poor weather, and weak colonies ... their operations. This is an increase from overall losses ...
... cognitive decline and for preventing Alzheimer,s diseasemental stimulation, ... studied over the years. However, an independent panel ... Health determined that the value of these strategies ... of decline or disease hasn,t been demonstrated in ...
... research team has taken a major step forward in understanding ... immune response by combining nanotechnology and cell biology. T cells ... response to infection. Christopher Cairo and his team ... cell response is switched on. Cairo looked at the molecule ...
Cached Biology News:Survey reports latest honey bee losses 2Panel finds insufficient evidence for Alzheimer's disease preventive measures 2Panel finds insufficient evidence for Alzheimer's disease preventive measures 3U Alberta-led team studies T cell activation with nanoparticles 2
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
in vitro Translation, Accessory Products...
Biology Products: